An intractable problem over drugs

January 1993
U.S. News & World Report;1/25/93, Vol. 114 Issue 3, p17
Reports that Parke-Davis, the only American maker of nitroglycerin pills--used to relieve angina pain--held back drug shipments last week because of manufacturing problems that might have altered the pills' potency. The Food and Drug Administration (FDA) persuaded the company to release reserve supplies. Other crucial drug shortages in the United States; How the FDA ended the previous shortages; How these shortages are viewed.


Related Articles

  • Parke-Davis puts $50 mil. in play. Kim, Hank // Adweek Western Edition;11/24/97, Vol. 47 Issue 47, p35 

    States that Parke-Davis, the pharmaceutical division of Warner-Lambert will review its two consumer advertising accounts. Identification of the accounts; Cost of the accounts.

  • Parke-Davis helps patients. Alvarado, Angeles // Caribbean Business;9/2/1993, Vol. 21 Issue 35, p27 

    Reports on Parke-Davis' educational program designed for hypertensive patients who use the company's product Accupril. Availability of program through a hot line; Quarterly information bulletins about cardiovascular illness prevention and exercise and diet programs.

  • Parke-Davis puts $5 mil. in play. Kim, Hank // Adweek New England Edition;11/24/97, Vol. 34 Issue 47, p35 

    Reports that Parke-Davis is reviewing two consumer advertising accounts. Reviews being overseen by Bob Ehrlich; Contenders for the accounts.

  • 3-D visualisation clears up molecular confusion.  // Design News;7/7/97, Vol. 53 Issue 13, p38 

    Cites the utilization of high-speed workstations, advanced modeling software and the 3-dimensional visualization capabilities of CrystalEyes eyewear, by Parke-Davis of Morris Plains, New Jersey, to test the interaction between molecules. Reasons for testing the molecules; Comment from Dan...

  • Parke-Davis puts $50 mil. in play. Kim, Hank // Adweek Midwest Edition;11/24/97, Vol. 38 Issue 47, p35 

    Focuses on the agency review conducted by Parke-Davis for its consumer advertising accounts. Estimated worth of the account; Agencies in contention for the account.

  • Xenova, Parke-Davis in drug collaboration.  // Chemical Market Reporter;11/4/96, Vol. 250 Issue 19, p17 

    Reports on agreement between Xenova Group PLC and Parke-Davis to collaborate on drug discovery.

  • Parke-Davis starts `Early Experience' program for femhrt. Roller, Kim // Drug Store News;2/21/2000, Vol. 22 Issue 2, p19 

    Reports that Parke-Davis has begun an outreach program for its continuous combined hormone replacement therapy, femhrt in 2000. Benefit of the program to women and physicians; Composition of femhrt.

  • Parke-Davis Coughs Up for Kids' Formula. Bittar, Christine // Brandweek;02/28/2000, Vol. 41 Issue 9, p6 

    Reports on the preparations of the Parke-Davis unit of Warner-Lambert for the spring 2000 introduction of Benadryl Fastmelt, a children's allergy and cold medication. Advertising budget; How the medication will be marketed; Objective behind the advertisement; Pending merger between...

  • Training for the Internet in a corporate environment. Marshall, Lucy; Carr, Janice // Computers in Libraries;Nov/Dec94, Vol. 14 Issue 10, p60 

    Focuses on the Internet training classes done in Parke-Davis. Introduction of the service-capability of Internet; Reasons for teaching an Internet class; Difference from Internet training classes for faculty and students; Course evaluation.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics